Caredx, Inc. shares closed at $87.50 on Friday, 30 October, their highest close in a year and 21.3% above the previous 52-week high of $72.13 set on 28 October 2026. Over the past year, the shares have risen 512.7%, excluding dividends.

Caredx's share price over the year

The 52-week range captures the full swing of the year. The shares closed between $14.28 and $72.13 over the previous 52 weeks. Over longer periods, they are up 1685.7% over three years and up 21.4% over five years, excluding dividends.

Profit is outgrowing sales

What stands out in the filings is that profit is outgrowing sales. Net income over the twelve months was $128.6 million, which rose 82.6% on the year before, against revenue growth of 38.9%. The trailing operating margin was 23.4%, up 6.8 percentage points from a year earlier; the trailing net margin was 25.9%.

Revenue over the twelve months to Q3 2026 was $497.4 million, up 38.9% on the year before. That growth rate was 4.5 percentage points higher than a quarter earlier.

Cash is outrunning sales. Operating cash flow over the twelve months was $69.0 million, up 62.2% on the year before. Capital spending, estimated from depreciation because the company no longer reports it in a standard form, was about $17.8 million, leaving free cash flow of about $51.2 million. Free cash flow rose 82.5% over the year.

The average diluted share count fell 9.3% over the year, so profit per share grows faster than profit itself.

Where Caredx's figures sit in its own record

Today's figures sit near the top of the company's own record. The free-cash-flow margin of 10.3% is higher than 92% of past quarterly readings, which have ranged from −64.3% to 17.3%. The operating margin of 23.4% is higher than 98% of past readings (−91.9% to 23.6%). The twelve-month revenue growth rate of 38.9% is higher than 62% of past readings (−13.9% to 80.5%).

The value hinges on margins more than growth

Our model's valuation is sensitive to the growth rate. A 5-percentage-point reduction in growth would lower the value by 21.5%, while a 5-percentage-point increase would raise it by 27.4%.

What Caredx's next report has to show

A 52-week high says where the price has gone, not why. The next results will show whether the trends in the filings support it.